Recovery & Tissue Repair Peptides

BPC-157 (Body Protection Compound) is the most widely studied peptide in this category, with a significant body of preclinical research spanning tendon, muscle, nerve, and gut tissue repair mechanisms. TB-500, derived from thymosin beta-4, has attracted research interest for its role in actin regulation and cellular migration — processes central to tissue healing responses.

Other peptides in this category include thymosin alpha-1, studied in immune modulation contexts, and glutathione, a tripeptide with antioxidant research spanning several decades. Provider availability and compounding status vary across this group; individual profiles note current dispensing status.

BPC-157 is most commonly studied in injectable form — typically subcutaneous administration near the target tissue — though oral delivery has been examined in gastrointestinal applications, consistent with BPC-157's origin as a gastric mucosal peptide fragment. Intranasal BPC-157 has been investigated in neurological and systemic contexts. TB-500 (thymosin beta-4 synthetic analogue) is similarly administered subcutaneously or intramuscularly, with research protocols using loading and maintenance phases. The BPC-157 and TB-500 combination is one of the more studied multi-peptide pairings in the recovery category — BPC-157's angiogenic and growth factor signaling mechanisms complement TB-500's actin-regulation and cellular migration effects, making the stack a common subject of musculoskeletal repair research. Providers offering these compounds are indexed in the PeptideBase directory.

Tissue healing involves overlapping biological processes: inflammation resolution, cellular proliferation, angiogenesis, and extracellular matrix remodelling. BPC-157 and TB-500 have been studied at different points in this cascade — which explains why research often examines them individually and in combination. None of the recovery peptides indexed here have received FDA approval specifically for healing indications; BPC-157 and TB-500 are available through 503A compounding, thymosin alpha-1 has specific international approvals detailed in its profile, and glutathione is available from a broader range of provider types.